Our results suggest that CD38 expression in CML cells can inhibit the ability of the cells to acquire BCR-ABL mutations upon IM treatment through regulating NAD+ metabolism. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.